Hansoh Pharmaceutical's (HKG:3692) attributable profit rose 33% to 4.37 billion yuan in 2024 from 3.28 billion yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share increased to 0.73 yuan from 0.52 yuan in the previous year.
Revenue grew 21% to 12.3 billion yuan from 10.1 billion yuan a year earlier.
The company declared a final dividend of HK$0.1353 per share, payable July 25 to shareholders on record as of July 9.